Tests LY4584180 in adults with previously treated blood cancers
Tests LY4584180 in adults with lymphoma that returned after earlier treatment.
Plain-language title generated from the registry record
Registry title: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Key facts
- Where
- Bologna and Milan, ItalySee the 2 sites
- Phase
- Phase 1
Where in Italy
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyNot yet recruiting
- Istituto Europeo di Oncologia s.r.lMilan, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07226843EU 2025-523601-16-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.Read full original descriptionShow less
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Inclusion: Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:; Diffuse large B-cell lymphoma - not otherwise specified; High-grade B-cell lymphoma; Diffuse large B-cell lymphoma - transformed from indolent lymphomas; Follicular large B-cell lymphoma; Follicular lymphoma; Other non-Hodgkin lymphoma; Has measurable disease; Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy.
Exclusion: Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval; Has an active second cancer; Has known Cytomegalovirus infection. Participants with negative status are eligible; Has known hepatitis B or C infection or uncontrolled HIV; Has known significant heart disease.